Dianthus Therapeutics Inc DE

For the period ended Mar 31, 2025. Filed May 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 12, 2025

DNTH$88.81-1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(in thousands, except share data)

Accumulated
Other · Total
Common Stock · Additional · Accumulated · Comprehensive · Stockholders’
	Shares	Amount	Paid-in Capital	Deficit	Income/(Loss)	Equity
Balance, December 31, 2024	31,115,341	$31	$526,732	$(174,392)	$106	$352,477
Exercise of pre-funded warrants	1,000,333	1	—	—	—	1
Exercise of stock options	3,321	—	31	—	—	31
Issuance of common stock under employee stock purchase plan (“ESPP”)	6,938	—	129	—	—	129
Stock-based compensation expense	—	—	5,315	—	—	5,315
Net loss	—	—	—	(29,511)	—	(29,511)
Unrealized gain on marketable securities	—	—	—	—	164	164
Balance, March 31, 2025	32,125,933	$32	$532,207	$(203,903)	$270	$328,606
Balance, December 31, 2023	14,817,696	$15	$258,231	$(89,423)	$47	$168,870
Issuance of common stock and pre-funded warrants in connection with the private placement, net of issuance costs of $14,665	14,500,500	14	215,319	—	—	215,333
Exercise of stock options	30,430	—	271	—	—	271
Stock-based compensation expense	—	—	2,035	—	—	2,035
Net loss	—	—	—	(13,748)	—	(13,748)
Unrealized loss on marketable securities	—	—	—	—	(74)	(74)
Balance, March 31, 2024	29,348,626	$29	$475,856	$(103,171)	$(27)	$372,687

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.